{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:16:53Z","timestamp":1793859413705,"version":"4.6.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Detection of neuronal surface antibodies (NSAb) is important for the diagnosis of autoimmune encephalitis (AE). Although most clinical laboratories use a commercial diagnostic kit (Euroimmun, L\u00fcbeck, Germany) based on indirect immunofluorescence on transfected cells (IIFA), clinical experience suggests diagnostic limitations. Here, we assessed the performance of the commercial IIFA in serum and CSF samples of patients with suspected AE previously examined by rat brain immunohistochemistry (Cohort A). Of 6213 samples, 404 (6.5%) showed brain immunostaining suggestive of NSAb: 163 (40%) were positive by commercial IIFA and 241 (60%) were negative. When these 241 samples were re-assessed with in-house IIFA, 42 (18%) were positive: 21 (9%) had NSAb against antigens not included in the commercial IIFA and the other 21 (9%) had NSAb against antigens included in the commercial kit (false negative results). False negative results occurred more frequently with CSF (29% vs 10% in serum) and predominantly affected GABA<jats:sub>B<\/jats:sub>R (39%), LGI1 (17%) and AMPAR (11%) antibodies. Results were reproduced in a separate cohort (B) of 54\u00a0AE patients with LGI1, GABA<jats:sub>B<\/jats:sub>R or AMPAR antibodies in CSF which were missed in 30% by commercial IIFA. Patients with discordant GABA<jats:sub>B<\/jats:sub>R antibody results (positive in-house but negative commercial IIFA) were less likely to develop full-blown clinical syndrome; no significant clinical differences were noted for the other antibodies. Overall, NSAb testing by commercial IIFA led to false negative results in a substantial number of patients, mainly those affected by anti-LG1, GABA<jats:sub>B<\/jats:sub>R or AMPAR encephalitis. If these disorders are suspected and commercial IIFA is negative, more comprehensive antibody studies are recommended.<\/jats:p>","DOI":"10.3389\/fimmu.2021.691536","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T06:53:23Z","timestamp":1624949603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":89,"title":["Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Raquel","family":"Ruiz-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mu\u00f1oz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Guasp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Graus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Martinez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A Clinical Approach to Diagnosis of Autoimmune Encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B2","unstructured":"Antibody-Mediated Encephalitis\n            DalmauJ\n            GrausF\n          2018"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00841","article-title":"Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis","volume":"9","author":"Ricken","year":"2018","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01385","article-title":"Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program","volume":"10","author":"Gastaldi","year":"2020","journal-title":"Front Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000404","article-title":"Improving the Antibody-Based Evaluation of Autoimmune Encephalitis","volume":"4","author":"McCracken","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh526","article-title":"Treatment-Responsive Limbic Encephalitis Identified by Neuropil Antibodies: MRI and PET Correlates","volume":"128","author":"Ances","year":"2005","journal-title":"Brain"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21589","article-title":"AMPA Receptor Antibodies in Limbic Encephalitis Alter Synaptic Receptor Location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"B8","unstructured":"Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies\n            DalmauJ\n            GleichmanAJ\n            HughesEG\n            RossiJE\n            PengX\n            LaiM\n          2008"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000916","article-title":"Seizure-Related 6 Homolog Like 2 Autoimmunity: Neurologic Syndrome and Antibody Effects","volume":"8","author":"Landa","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABAB Receptor in Limbic Encephalitis With Seizures: Case Series and Characterisation of the Antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"B11","unstructured":"Investigation of LGI1 as the Antigen in Limbic Encephalitis Previously Attributed to Potassium Channels: A Case Series\n            LaiM\n            HuijbersMGM\n            LancasterE\n            GrausF\n            BatallerL\n            Balice-GordonR\n          2010"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22297","article-title":"Investigations of Caspr2, an Autoantigen of Encephalitis and Neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis With Refractory Seizures, Status Epilepticus, and Antibodies to the GABAA Receptor: A Case Series, Characterisation of the Antigen, and Analysis of the Effects of Antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A Novel non-Rapid-Eye Movement and Rapid-Eye-Movement Parasomnia With Sleep Breathing Disorder Associated With Antibodies to Iglon5: A Case Series, Characterisation of the Antigen, and Post-Mortem Study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis With mGluR5 Antibodies: Symptoms and Antibody Effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000658","article-title":"Paraneoplastic Cerebellar Ataxia and Antibodies to Metabotropic Glutamate Receptor 2","volume":"7","author":"Ruiz-Garc\u00eda","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010854","article-title":"Clinical Features, Prognostic Factors, and Antibody Effects in Anti-Mglur1 Encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy253","article-title":"LGI1 Antibodies Alter K V 1.1 and AMPA Receptors Changing Synaptic Excitability, Plasticity and Memory","volume":"141","author":"Petit-Pedrol","year":"2018","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24979","article-title":"Expanded Phenotypes and Outcomes Among 256 LGI1\/CASPR2-Igg\u2013Positive Patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 Encephalitis: Clinical Syndrome and Long-Term Follow-Up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz094","article-title":"The Expanded Clinical Spectrum of Anti-GABABR Encephalitis and Added Value of KCTD16 Autoantibodies","volume":"142","author":"Van Coevorden-Hameete","year":"2019","journal-title":"Brain"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody Titres at Diagnosis and During Follow-Up of Anti-NMDA Receptor Encephalitis: A Retrospective Study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.24189","article-title":"Seroprevalence of Autoantibodies Against Brain Antigens in Health and Disease","volume":"76","author":"Dahm","year":"2014","journal-title":"Ann Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.110","article-title":"Neuropsychiatric Disease Relevance of Circulating Anti-NMDA Receptor Autoantibodies Depends on Blood-Brain Barrier Integrity","volume":"19","author":"Hammer","year":"2014","journal-title":"Mol Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.008323","article-title":"Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke","volume":"46","author":"Zerche","year":"2015","journal-title":"Stroke"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1-Associated Cognitive Impairment","volume":"87","author":"Ari\u00f1o","year":"2016","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.691536\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T06:53:26Z","timestamp":1624949606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.691536\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2021.691536"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.691536","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"article-number":"691536"}}